MOLN — Molecular Partners AG

Summary of MOLN Q4 2024 Earnings Call

1. Key Financial Results and Metrics

• Revenue: CHF 5 million for 2024, exclusively from the Novartis collaboration, which has now concluded.
• Operating Expenses: CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D.
• Net Financial Result: Benefited from high interest rates on U.S. dollar deposits.
• Cash Position: Ended the year with CHF 149 million, down from CHF 187 million, indicating a cash burn of CHF 54 million for the year. The company remains debt-free and well-capitalized through 2027.

2. Strategic Updates and Business Highlights

• DLL3 Radio DARPin Program: The lead compound, MP0712, has passed IND-enabling studies and is set to enter clinical trials. A new target, mesothelin, has also been selected for development.
• Collaboration with Orano Med: Expanded partnership secured access to 10 product slots for Lead-212 isotopes, critical for their radio DARPin programs.
• T Cell Engager Program (533): Adjustments made to dosing regimens have shown promising initial results in AML, with plans to enhance dosing frequency and effectiveness.
• Financing: A CHF 20 million financing round was completed, strengthening the company’s financial position.

3. Forward Guidance and Outlook

• 2025 Guidance: Operating expenses are projected to be between CHF 55 million and CHF 65 million, with no revenue guidance provided. The company expects to initiate clinical data collection for MP0712 in 2025, with initial results anticipated in early 2026.
• Clinical Programs: The company is optimistic about achieving first clinical data from the DLL3 program and further developments in the T cell engager program.

4. Bad News, Challenges, or Points of Concern

• Novartis Collaboration Discontinuation: The collaboration with Novartis on two targets was terminated due to a lack of strategic interest and progress, indicating potential setbacks in their research pipeline.
• DLL3 Target Risks: While DLL3 is seen as a validated target, there are concerns about on-target off-tumor effects, particularly in the pituitary gland, which may require careful monitoring.
• Market Competition: The company faces competition in the radio therapy space, and there is uncertainty regarding the efficacy of new targets like mesothelin, which has previously seen failures in other modalities.

5. Notable Q&A Insights

• IND Submission for MP0712: The company aims to conduct Phase 0 imaging and Phase I therapeutic dosing in parallel, pending FDA approval.
• Mesothelin as a Target: The team expressed cautious optimism about mesothelin, citing high medical need in ovarian cancer, but acknowledged the challenges posed by previous failures in targeting this antigen.
• Partnership Strategy: The company is open to both candidate-specific and platform-wide partnerships, indicating flexibility in their approach to collaborations.
• DLL3 Kidney Ratio: The team emphasized the importance of achieving a favorable tumor-to-kidney ratio, ideally above 2:1, while recognizing that patient variability may affect this outcome.

Overall, Molecular Partners is positioned for a pivotal year ahead, with significant developments in their clinical programs and a solid financial foundation, despite facing challenges in partnerships and market competition.